+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Chronic Refractory Cough Market by Drug Type (Amitriptyline, Gabapentin, Pregabalin), Distribution Channel (Drug Store, Hospital Pharmacies, Online Pharmacies) - Forecast 2024-2030- Product Image
Global Chronic Refractory Cough Market by Drug Type (Amitriptyline, Gabapentin, Pregabalin), Distribution Channel (Drug Store, Hospital Pharmacies, Online Pharmacies) - Forecast 2024-2030- Product Image
Sale

Global Chronic Refractory Cough Market by Drug Type (Amitriptyline, Gabapentin, Pregabalin), Distribution Channel (Drug Store, Hospital Pharmacies, Online Pharmacies) - Forecast 2024-2030

  • PDF Icon

    Report

  • 181 Pages
  • May 2024
  • Region: Global
  • 360iResearch™
  • ID: 5968261
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Chronic Refractory Cough Market size was estimated at USD 5.57 billion in 2023, USD 5.88 billion in 2024, and is expected to grow at a CAGR of 5.88% to reach USD 8.32 billion by 2030.

The Chronic Refractory Cough (CRC) market involves addressing a persistent cough that remains unresponsive to traditional treatments for more than eight weeks. Rising incidences of chronic respiratory conditions such as asthma, COPD, and bronchitis naturally lead to an increase in cases of chronic refractory coughs. Improved healthcare infrastructure and heightened awareness about CRC have led more individuals to seek treatment for chronic coughs, thus expanding the market. Innovative therapeutic approaches and advancements in medical technologies that offer higher efficacy in treating or managing CRC are also critical growth drivers in the market.

However, CRC can often be misdiagnosed or overlooked as its symptoms may resemble those of other less severe illnesses, which can impede effective treatment. Some current treatments available have significant side effects, which might deter patients, creating challenges for continuing with their prescribed therapies. Moreover, there is a substantial opportunity for growth through the development of new pharmaceutical formulations and advanced therapeutic devices designed specifically for CRC management. Integrating CRC management with telehealth platforms can enhance accessibility for patients struggling with this condition, facilitating continuous management without frequent hospital visits.

Regional Insights

In the Americas region, the U.S. and Canada represent a substantial market for the management of chronic refractory cough due to its advanced healthcare infrastructure and high awareness levels regarding respiratory conditions. Recent patents in the U.S. have focused on novel cough suppressant therapies and cough management devices, highlighting a trend toward technological integration in treatment. The EU market is guided by stringent regulations that drive the demand for highly effective and safe treatments. Consumer behavior in the EU is characterized by a preference for evidence-based therapies. In the Middle East, there is increasing awareness and healthcare expenditure concerning chronic diseases, including CRC.

The Middle East region shows growing interest in specialized healthcare services and international collaborations for advanced treatment methods. Recent initiatives in the African region aim to improve healthcare infrastructure and accessibility, which may increase the demand for CRC management solutions in the long term. In the APAC region, China has seen rapid health infrastructure improvements, which extend to the management of chronic coughs. CRC treatment in Japan often involves cutting-edge technology and pharmaceuticals supported by government-backed healthcare policies. Japan’s aging population also makes it a critical market for CRC management solutions. In India, the rising middle class and improvements in healthcare facilities are creating significant opportunities for CRC management.

Market Trends by Segment

  • Drug Type: Exploring gabapentin for innovative treatments for chronic refractory cough with neuropathic links
  • Distribution Channel: Increasing preference to online pharmacies for chronic refractory cough treatment

Industry Insights

  • Market Dynamics
  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis
  • FPNV Positioning Matrix
  • Market Share Analysis
  • Strategy Analysis and Recommendations

Recent Developments

Investment Surge in Novel Respiratory Therapeutics: Focus on Nocion Therapeutics' Development of Taplucanium for Chronic Refractory Cough

Nocion Therapeutics, based in Watertown, Massachusetts, has completed a USD 62 million Series B funding round to advance the development of their innovative drug, taplucanium. Nocion is pioneering a novel approach by targeting the nociceptors - sensory neurons that trigger pain, itching, or coughs - which are implicated in various conditions including chronic refractory cough, a difficult-to-treat condition characterized by a persistent cough without a clear underlying cause

Trevi Therapeutics Launches Phase 2a RIVER Trial for Haduvio, Advancement in Refractory Chronic Cough Treatment

Trevi Therapeutics, Inc., a pioneering company in clinical-stage biopharmaceuticals, recently initiated the Phase 2a RIVER clinical trial to assess the efficacy of Haduvio (oral nalbuphine ER) in treating patients with refractory chronic cough (RCC). The RIVER trial, a rigorous double-blind, placebo-controlled study with a 2-period crossover design, aims to enroll approximately 60 participants who suffer from moderate to severe cough frequencies

GSK PLC Finalizes Acquisition of BELLUS Health Inc. Health to Enhance Chronic Refractory Cough Treatment Portfolio

GSK PLC has acquired BELLUS Health Inc., integrating BELLUS Health Inc.'s promising drug candidate, camlipixant, a highly selective P2X3 antagonist into its respiratory therapy lineup. Camlipixant, now in phase III trials, targets the first line treatment of adult patients with refractory chronic cough. The transaction, endorsed by BELLUS Health Inc. shareholders to leverage GSK PLC's robust R&D, manufacturing, and commercialization capabilities to expedite the drug's market launch.

Key Company Profiles

The report delves into recent significant developments in the Chronic Refractory Cough Market, highlighting leading vendors and their innovative profiles. These include Accord Healthcare Inc., Alitair Pharmaceuticals, Amneal Pharmaceuticals Inc., Apotex Inc., AstraZeneca PLC, Aurobindo Pharma Ltd, Bausch Health, Bayer AG, Cipla Inc., Dr Reddy's Laboratories Ltd., Glenmark Pharmaceuticals Ltd., GSK PLC, Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Ltd., Mylan N.V. by Viatris Inc., NeRRe Therapeutics, Novartis AG, Pfizer Inc., Sienna Biotec, Strides Pharma, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Unichem Laboratories Ltd. by Ipca Labs, and Zydus Pharmaceuticals USA Inc.

This research report offers invaluable insights into various crucial aspects of the Chronic Refractory Cough Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of chronic refractory cough
5.1.1.2. Government support for awareness and early diagnosis
5.1.2. Restraints
5.1.2.1. Potential risk of drug recall
5.1.3. Opportunities
5.1.3.1. Increasing R&D initiatives toward effective drug development
5.1.3.2. Collaborative drug development and improving healthcare expenditure
5.1.4. Challenges
5.1.4.1. Side effects associated CRC treatment
5.2. Market Segmentation Analysis
5.2.1. Drug Type: Exploring gabapentin for innovative treatments for chronic refractory cough with neuropathic links
5.2.2. Distribution Channel: Increasing preference to online pharmacies for chronic refractory cough treatment
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Chronic Refractory Cough Market, by Drug Type
6.1. Introduction
6.2. Amitriptyline
6.3. Gabapentin
6.4. Pregabalin
7. Chronic Refractory Cough Market, by Distribution Channel
7.1. Introduction
7.2. Drug Store
7.3. Hospital Pharmacies
7.4. Online Pharmacies
8. Americas Chronic Refractory Cough Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Chronic Refractory Cough Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Chronic Refractory Cough Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
11.3.1. Investment Surge in Novel Respiratory Therapeutics: Focus on Nocion Therapeutics' Development of Taplucanium for Chronic Refractory Cough
11.3.2. Trevi Therapeutics Launches Phase 2a RIVER Trial for Haduvio, Advancement in Refractory Chronic Cough Treatment
11.3.3. GSK PLC Finalizes Acquisition of BELLUS Health Inc. Health to Enhance Chronic Refractory Cough Treatment Portfolio
11.4. Strategy Analysis & Recommendation
12. Competitive Portfolio
12.1. Key Company Profiles
12.2. Key Product Portfolio
List of Figures
FIGURE 1. CHRONIC REFRACTORY COUGH MARKET RESEARCH PROCESS
FIGURE 2. CHRONIC REFRACTORY COUGH MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CHRONIC REFRACTORY COUGH MARKET DYNAMICS
FIGURE 7. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 8. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 10. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. CHRONIC REFRACTORY COUGH MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 20. CHRONIC REFRACTORY COUGH MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. CHRONIC REFRACTORY COUGH MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY AMITRIPTYLINE, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY AMITRIPTYLINE, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY GABAPENTIN, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY GABAPENTIN, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY PREGABALIN, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY PREGABALIN, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG STORE, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG STORE, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 24. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 25. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 26. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 27. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 28. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 29. ARGENTINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 30. ARGENTINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 31. ARGENTINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 32. ARGENTINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 33. BRAZIL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 34. BRAZIL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 35. BRAZIL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 36. BRAZIL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 37. CANADA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 38. CANADA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 39. CANADA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 40. CANADA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 41. MEXICO CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 42. MEXICO CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 43. MEXICO CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 44. MEXICO CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 45. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 46. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 47. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 48. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 49. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 50. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 52. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 53. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 54. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 55. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 56. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 57. AUSTRALIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 58. AUSTRALIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 59. AUSTRALIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 60. AUSTRALIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 61. CHINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 62. CHINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 63. CHINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 64. CHINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 65. INDIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 66. INDIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 67. INDIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 68. INDIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 69. INDONESIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 70. INDONESIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 71. INDONESIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 72. INDONESIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 73. JAPAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 74. JAPAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 75. JAPAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 76. JAPAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 77. MALAYSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 78. MALAYSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 79. MALAYSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 80. MALAYSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 81. PHILIPPINES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 82. PHILIPPINES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 83. PHILIPPINES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 84. PHILIPPINES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 85. SINGAPORE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 86. SINGAPORE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 87. SINGAPORE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 88. SINGAPORE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 89. SOUTH KOREA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 90. SOUTH KOREA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 91. SOUTH KOREA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 92. SOUTH KOREA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 93. TAIWAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 94. TAIWAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 95. TAIWAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 96. TAIWAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 97. THAILAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 98. THAILAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 99. THAILAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 100. THAILAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 101. VIETNAM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 102. VIETNAM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 103. VIETNAM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 104. VIETNAM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 111. DENMARK CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 112. DENMARK CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 113. DENMARK CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 114. DENMARK CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 115. EGYPT CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 116. EGYPT CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 117. EGYPT CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 118. EGYPT CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 119. FINLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 120. FINLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 121. FINLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 122. FINLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 123. FRANCE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 124. FRANCE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 125. FRANCE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 126. FRANCE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 127. GERMANY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 128. GERMANY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 129. GERMANY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 130. GERMANY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 131. ISRAEL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 132. ISRAEL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 133. ISRAEL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 134. ISRAEL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 135. ITALY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 136. ITALY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 137. ITALY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 138. ITALY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 139. NETHERLANDS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 140. NETHERLANDS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 141. NETHERLANDS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 142. NETHERLANDS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 143. NIGERIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 144. NIGERIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 145. NIGERIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 146. NIGERIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 147. NORWAY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 148. NORWAY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 149. NORWAY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 150. NORWAY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 151. POLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 152. POLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 153. POLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 154. POLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 155. QATAR CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 156. QATAR CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 157. QATAR CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 158. QATAR CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 159. RUSSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 160. RUSSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 161. RUSSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 162. RUSSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 164. SAUDI ARABIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 165. SAUDI ARABIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 166. SAUDI ARABIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 168. SOUTH AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 170. SOUTH AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 171. SPAIN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 172. SPAIN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 173. SPAIN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 174. SPAIN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 175. SWEDEN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 176. SWEDEN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 177. SWEDEN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 178. SWEDEN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 179. SWITZERLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 180. SWITZERLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 181. SWITZERLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 182. SWITZERLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 183. TURKEY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 184. TURKEY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 185. TURKEY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 186. TURKEY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 192. UNITED KINGDOM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 194. UNITED KINGDOM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 195. CHRONIC REFRACTORY COUGH MARKET SHARE, BY KEY PLAYER, 2023
TABLE 196. CHRONIC REFRACTORY COUGH MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

  • Accord Healthcare Inc.
  • Alitair Pharmaceuticals
  • Amneal Pharmaceuticals Inc.
  • Apotex Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Ltd
  • Bausch Health
  • Bayer AG
  • Cipla Inc.
  • Dr Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • GSK PLC
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Ltd.
  • Mylan N.V. by Viatris Inc.
  • NeRRe Therapeutics
  • Novartis AG
  • Pfizer Inc.
  • Sienna Biotec
  • Strides Pharma
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Unichem Laboratories Ltd. by Ipca Labs
  • Zydus Pharmaceuticals USA Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages181
PublishedMay 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 5.88 Billion
Forecasted Market Value ( USD ) by 2030 $ 8.32 Billion
Compound Annual Growth Rate5.8%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Chronic Refractory Cough Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Chronic Refractory Cough Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 132 Pages
  • Global
From
Chronic Refractory Cough - Pipeline Insight, 2024 - Product Image

Chronic Refractory Cough - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Global Cough Remedies Market Size, Share & Trends Analysis Report By Age (Adult and Pediatric), By Distribution Channel (Retail Pharmacy, Hospital and Online Pharmacies), By Type, By Dosage. By Regional Outlook and Forecast, 2023 - 2030 - Product Image

Global Cough Remedies Market Size, Share & Trends Analysis Report By Age (Adult and Pediatric), By Distribution Channel (Retail Pharmacy, Hospital and Online Pharmacies), By Type, By Dosage. By Regional Outlook and Forecast, 2023 - 2030

  • Report
  • 266 Pages
  • Global
From
Asia Pacific Cough Remedies Market Size, Share & Trends Analysis Report By Age (Adult and Pediatric), By Distribution Channel (Retail Pharmacy, Hospital and Online Pharmacies), By Type, By Dosage. By Country and Growth Forecast, 2023 - 2030 - Product Image

Asia Pacific Cough Remedies Market Size, Share & Trends Analysis Report By Age (Adult and Pediatric), By Distribution Channel (Retail Pharmacy, Hospital and Online Pharmacies), By Type, By Dosage. By Country and Growth Forecast, 2023 - 2030

  • Report
  • 125 Pages
  • Asia Pacific
From
Chronic Cough Global Market Report 2024 - Product Image

Chronic Cough Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From

About the Chronic Refractory Cough Drugs Market

The Chronic Refractory Cough Drugs market is a subset of the larger Respiratory Drugs market. It is composed of drugs used to treat chronic refractory cough, a condition characterized by a persistent cough that does not respond to conventional treatments. These drugs are typically used in combination with other treatments, such as lifestyle modifications, to reduce the severity of the cough. Commonly used drugs include anticholinergics, antihistamines, and mucolytics. These drugs are used to reduce inflammation, reduce mucus production, and reduce airway irritation. The Chronic Refractory Cough Drugs market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include GlaxoSmithKline, Merck & Co., Pfizer, AstraZeneca, and Novartis. Other companies include Sanofi, Boehringer Ingelheim, and Sun Pharmaceuticals. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.